In an implanted mouse model of metastatic osteosarcoma, treatment with anti-PD-L1 antibody reduced the expression of PD-L1, increased the expression of CD80/CD86 in tumor cells, and increased the expression of CTLA-4 in tumor-infiltrating CD8+ T cells. The gene discussed is CD86; the disease is neoplasm.